CVS Health Stock Performance Amid Financial Recovery

• •CVS Health's stock has increased by 31% over the past year.
• •The company reported Q2 2026 revenue of $106.1 billion, up 7.3% year over year.
• •CVS is focusing on the growing weight-loss drug market to drive future growth.

CVS Health has shown significant financial recovery post-COVID-19, with a 31% stock increase over the past year. The company reported a 7.3% revenue growth to $106.1 billion in Q2 2026, alongside a 42.5% rise in adjusted earnings per share (EPS). CVS has improved its operational efficiency, reducing operating expenses as a percentage of revenue. The company is also focusing on the expanding weight-loss market, offering consultations for GLP-1 prescriptions. Despite recent stock fluctuations, analysts maintain a positive outlook with an average price target of around $116.04. However, concerns remain regarding potential membership declines and regulatory scrutiny affecting its pharmacy benefit manager segment. Overall, CVS Health is positioned for growth with a strong dividend history and improved financial guidance for the fiscal year.